UroGen Pharma Ltd. (URGN) key performance indicators and operating metrics (6 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Gelmito Net Product Revenue | 21.7M | FY2026-Q1 |
| Activated Sites of Care (ZUSDURI) | 972.00 | FY2026-Q1 |
| Repeat ZUSDURI Prescribers | 103.00 | FY2026-Q1 |
| Unique ZUSDURI Prescribers | 256.00 | FY2026-Q1 |
| ZUSDURI Net Product Revenue | 29.2M | FY2026-Q1 |
| Interest Expense Related to Term Loan Facility | -3.77M | FY2025-Q4 |
Back to URGN overview · URGN earnings · URGN holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.